Anti-Inflammatory Biologics Market Report 2025

The anti-inflammatory biologics market size has grown strongly in recent years. It will grow from $108.11 billion in 2024 to $118.02 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth during the historic period can be attributed to the rising prevalence of arthritis, increased awareness of autoimmune diseases, the growing introduction of new biologics, expanding healthcare infrastructure, and a rise in regulatory approvals.

The anti-inflammatory biologics market size is expected to see strong growth in the next few years. It will grow to $166.28 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to the increasing adoption of biologics, rising demand for targeted therapies, growing patient preference for long-term remission, expanded use of biomarkers for disease monitoring, and the increasing demand for personalized medicine. Key trends expected during this period include advancements in biologic drug development, the emergence of oral biologics for inflammation, technology-driven drug delivery systems, progress in biosimilars, and improvements in diagnostic tools.

The increasing prevalence of arthritis is expected to drive the growth of the anti-inflammatory biologics market. Arthritis involves inflammation or swelling in one or more joints, resulting in pain, stiffness, and limited movement, often worsening with age. The rise in arthritis cases is largely linked to increasing obesity rates, as excess weight adds stress to the joints, causing inflammation and degeneration. Anti-inflammatory biologics work by targeting specific parts of the immune system to reduce inflammation, slow joint damage, alleviate symptoms, and enhance physical function and quality of life for individuals with moderate to severe arthritis. For example, in March 2023, the UK’s Office for Health Improvement and Disparities reported that in 2022, 17.6% of people aged 16 and older had a long-term musculoskeletal condition like arthritis or persistent back or joint issues, up from 17% in 2021. This growing prevalence of arthritis is driving market expansion.

Companies in the anti-inflammatory biologics market are developing advanced treatments such as interleukin-6 (IL-6) receptor antagonists to more precisely target chronic inflammatory diseases while minimizing side effects. IL-6 receptor antagonists are biologic drugs that inhibit the IL-6 receptor, reducing inflammation and immune response in conditions such as rheumatoid arthritis. For instance, in February 2023, Regeneron Pharmaceuticals Inc., a US biotechnology firm, received FDA approval for Kevzara as the first biologic specifically indicated for patients with polymyalgia rheumatica (PMR) who do not respond adequately to corticosteroids. Kevzara is a fully human monoclonal antibody that blocks the IL-6 receptor to decrease inflammation associated with PMR, a disease causing muscle pain and stiffness, mainly in older adults. Unlike traditional steroids, which carry risks like osteoporosis and diabetes with long-term use, Kevzara offers a targeted, steroid-sparing alternative that promotes better patient outcomes and long-term safety.

In October 2023, Amgen Inc., a US-based biopharmaceutical company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen’s position in innovative treatments for serious illnesses by expanding its portfolio in rare and autoimmune diseases, accelerating growth, and extending its reach to more patients worldwide with first-in-class therapies. Horizon Therapeutics plc, based in Ireland, focuses on developing several anti-inflammatory biologics.

Major players in the anti-inflammatory biologics market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, AbbVie Inc, Sanofi S.A, Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Amgen Inc., Regeneron Pharmaceuticals Inc, Biogen Inc., UCB S.A, UCB S.A./N.V, Swedish Orphan Biovitrum AB, Almirall S.A., Evotec SE, and Hansa Biopharma AB.

North America was the largest region in the anti-inflammatory biologics market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in anti-inflammatory biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-inflammatory biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-inflammatory biologics market consists of sales of adalimumab, etanercept, infliximab, ustekinumab, and secukinumab. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-inflammatory biologics market research report is one of a series of new reports that provides anti-inflammatory biologics market statistics, including anti-inflammatory biologics global market size, regional shares, competitors with anti-inflammatory biologics market share, detailed anti-inflammatory biologics market segments, market trends and opportunities, and any further data you may need to thrive in the anti-inflammatory biologics industry. The anti-inflammatory biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-inflammatory biologics are therapeutic drugs derived from living organisms that specifically target elements of the immune system to reduce inflammation. They are widely used to treat chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease by inhibiting cytokines or immune cells responsible for triggering inflammation.

The main drug classes of anti-inflammatory biologics include tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors, T-cell inhibitors, and others. Tumor necrosis factor inhibitors are biologic drugs that block the activity of tumor necrosis factor-alpha, a substance in the body that causes inflammation, helping to alleviate symptoms in autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease. These medications are administered via various routes, including oral, injection, intravenous, and subcutaneous methods. They are commonly used for applications such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, among others, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and more. The end users of these biologics include hospitals, clinics, home care settings, and research and academic institutions.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.